EMA Withdrawn: Budesonide/Formoterol Teva (Budesonide;formoterol fumarate dihydrate) — Teva Pharma B.V.

View source ↗

Summary

EMA confirms withdrawal of Budesonide/Formoterol Teva, a combination inhaled therapy, from the product market.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Asthma
• Chronic Obstructive Pulmonary Disease

Drugs mentioned

• Budesonide/Formoterol Teva (budesonide; formoterol fumarate dihydrate)

Snippet

Status: Withdrawn. Therapeutic area: Pulmonary Disease, Chronic Obstructive;Asthma. MAH: Teva Pharma B.V.. Decision date: 16/12/2016